Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

ABBOTT LABORATORIES

(ABT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
02/17/2021 02/18/2021 02/19/2021 02/22/2021 02/23/2021 Date
127.24(c) 125.41(c) 123.04(c) 122.55(c) 120.8(c) Last
3 162 043 5 435 012 6 204 206 4 842 190 5 566 064 Volume
-0.61% -1.44% -1.89% -0.40% -1.43% Change
More quotes
Financials (USD)
Sales 2021 42 318 M - -
Net income 2021 7 394 M - -
Net Debt 2021 8 762 M - -
P/E ratio 2021 29,8x
Yield 2021 1,33%
Sales 2022 42 267 M - -
Net income 2022 8 313 M - -
Net Debt 2022 4 741 M - -
P/E ratio 2022 27,0x
Yield 2022 1,42%
Capitalization 214 B 214 B -
EV / Sales 2021 5,26x
EV / Sales 2022 5,18x
Nbr of Employees 109 000
Free-Float 88,8%
More Financials
Company
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Company focuses on cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicine. It offers products,... 
More about the company
Notations Surperformance© of Abbott Laboratories
Trading Rating : Investor Rating :
More Ratings
All news about ABBOTT LABORATORIES
11:55aSENSOR PATCH MARKET SIZE, TRENDS AND : Abbott Laboratories, Irhythm Technologies..
AQ
02/22ABBOTT LABORATORIES : Declares 389th consecutive quarterly dividend
AQ
02/19ABBOTT LABORATORIES : Change in Directors or Principal Officers, Amendments to A..
AQ
02/19ABBOTT LABORATORIES : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITIO..
AQ
02/19ABBOTT LABORATORIES : Declares Quarterly Dividend of $0.45 a Share; Payable May ..
MT
02/19ABBOTT : Declares 389th Consecutive Quarterly Dividend
PR
02/18INSIDER TRENDS : Abbott Laboratories Insider Sells Shares for Tax Slowing 90-Day..
MT
02/18INSIDER TRENDS : Abbott Laboratories Insider Makes Tax Sale Interrupting 90-Day ..
MT
02/04INSIDER TRENDS : Insider at Abbott Laboratories Acquires Stock Via Option/Deriva..
MT
02/04Roche sees 2021 growth, buoyed by COVID tests as pandemic persists
RE
01/28ABBOTT LABORATORIES : JP Morgan Adjusts Price Target for Abbott Laboratories to ..
MT
01/28ABBOTT LABORATORIES : Cowen Adjusts Abbott Laboratories' Price Target to $140 Fr..
MT
01/28ABBOTT LABORATORIES : Raymond James Adjusts Price Target on Abbott Laboratories ..
MT
01/28ABBOTT LABORATORIES : SVB Leerink Adjusts Price Target on Abbott Laboratories to..
MT
01/28ABBOTT LABORATORIES : Wells Fargo Adjusts Abbott Laboratories' Price Target to $..
MT
More news
News in other languages on ABBOTT LABORATORIES
02/04Des marchés en pause sous un déluge de résultats
02/04EN DIRECT DES MARCHES : Dassault Systèmes, Carrefour, Stellantis, Air France-KLM..
01/27MÄRKTE USA/Wall Street nach Fed-Aussagen mit kräftigen Abschlägen
01/27MÄRKTE USA/Wall Street vor Fed-Entscheid mit kräftigen Abschlägen
01/27MÄRKTE USA/Wall Street startet mit deutlichen Abschlägen
More news
Analyst Recommendations on ABBOTT LABORATORIES
More recommendations
Stock Trading Strategies
ABBOTT LABORATORIES - 01/20
Close to a key resistance level
BUY
More Stock Trading Analysis
Chart ABBOTT LABORATORIES
Duration : Period :
Abbott Laboratories Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 133,39 $
Last Close Price 120,80 $
Spread / Highest target 30,8%
Spread / Average Target 10,4%
Spread / Lowest Target -23,0%
EPS Revisions
Managers and Directors
NameTitle
Robert B. Ford President, CEO, Chief Operating Officer & Director
Robert E. Funck Chief Financial Officer & Executive Vice President
Miles D. White Executive Chairman
Roxanne Schuh Austin Independent Director
Samuel C. Scott Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ABBOTT LABORATORIES11.93%214 001
MEDTRONIC PLC-1.19%159 002
BECTON, DICKINSON AND COMPANY-1.01%71 972
HOYA CORPORATION-13.00%45 798
ALIGN TECHNOLOGY, INC.8.45%44 772
SARTORIUS STEDIM BIOTECH26.51%41 293